Abstract 1014TiP
Background
Currently, 70%-80% of liver cancer patients have recurrence within 5 years after radical surgery. Therefore, determining effective treatment methods for liver cancer is still a major issue of global concern. Recombinant human adenovirus type 5 (rAd5, H101) is the world's first approved oncolytic virus product in China, rAd5 and transarterial chemoembolization (TACE) has significant anti-tumor effect in treatment of liver cancer. Compared with TACE, transhepatic arterial embolization (TAE) sequential thermal ablation may significantly improve the overall survival (OS) rate of liver cancer patients. This study aims to explore the efficacy and safety of rAd5 combined with TAE sequential thermal ablation in treatment of liver cancer, and to further explore the local and systemic immunological changes in patients.
Trial design
This is a prospective, open-label, randomized, parallel controlled study, 110 patients with medium- and high-risk recurrent liver cancer are expected to enroll. Key inclusion criteria are: age ≥18 and ≤70; ECOG performance status of 0-1; Child-Pugh score ≤7; and the expected survival time ≥3 months. All participants are randomized 1:1 to receive rAd5 combined with TAE and thermal ablation (experimental group) or TAE and thermal ablation (control group). Before, 10 mg dexamethasone was intravenously administered. rAd5 (H101) will be intratumorally injected into the hepatic segmental artery, the dosage is adjusted according to the maximum diameter of lesions: ≤10 cm, 1.0×1012 vp/day; ≥10 cm, 1.5×1012 vp/ day, 28 days for a cycle (4 cycles totally). 1-3 weeks after rAd5 injection and TAE or TAE, thermal ablation treatment will be performed if patients have residual tumor. Patients will be followed up at 1, 3, 6 and 12 months after treatment. The primary endpoint is objective response rate. Secondary endpoints include progression free survival, disease control rate, one-year OS and quality of life score. Exploratory endpoints are the changes from baseline in CD4+, CD8+, Treg, Th1 and Th2. The adverse events will be monitored.
Clinical trial identification
ChiCTR2300067319 (http://www.chictr.org.cn/); Release date, January 04, 2023.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
956P - Phase II study of adjuvant tislelizumab combined with interferon-α and active surveillance in hepatocellular carcinoma patients with microvascular invasion
Presenter: Yixiu Wang
Session: Poster session 18
957P - Interim report of Notable-HCC: A phase Ib study of neoadjuvant PD-1 with stereotactic body radiotherapy in patients with resectable hepatocellular carcinoma (HCC)
Presenter: Mingming Li
Session: Poster session 18
959P - Combination therapy of envafolimab and suvemcitug in patients with hepatocellular carcinoma (HCC): Results from a phase II clinical trial
Presenter: Lixia Ma
Session: Poster session 18
960P - Personalized circulating tumor DNA (ctDNA) monitoring for recurrence detection and treatment response assessment in hepatocellular carcinoma (HCC)
Presenter: Maen Abdelrahim
Session: Poster session 18
961P - Blood circulating Galectin-3 is a prognostic biomarker in hepatocellular carcinoma
Presenter: Shadi Chamseddine
Session: Poster session 18
962P - SBRT improves the efficacy of immuno-checkpoint inhibitors for hepatocellular carcinoma through the activation of IL-6/JAK1-STAT3/PD-L1 axis mediated by MBD3 degradation
Presenter: Weiwei Yan
Session: Poster session 18
963P - Discovery and validation of cfDNA methylation, AFP and ctDNA mutation for the early detection of hepatocellular carcinoma: A multicenter prospective study (ASCEND-Hep)
Presenter: Mingxin Pan
Session: Poster session 18
966P - Potential role of neuropilin-1 in the prognosis, development and risk of invasion in hepatocellular carcinoma patients
Presenter: Tania Payo-Serafín
Session: Poster session 18